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Abstract MFE23 is a single chain Fv antibody that has a high
affinity for carcinoembryonic antigen (CEA). A full homology
model for CEA based on V-type, I-type and C2-type immuno-
globulin folds, 28 oligosaccharides and the interdomain angle of
CD2 was validated using solution scattering data. The super-
imposition of the intermolecular contacts observed in our recent
crystal structure of MFE23 with the N-terminal domain of CEA
permitted the MFE23^CEA complex to be modelled. Good
surface and electrostatic complementarity and carbohydrate-
unhindered access of MFE23 with the indentation between the
first two CEA domains was observed. The model is supported by
biochemical data and provides insight on the high affinity of
MFE23 for CEA. ß 2000 Federation of European Biochemi-
cal Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Antibodies and cell surface proteins represent two major
groups of the immunoglobulin (Ig) superfamily [1]. While
antibodies are constructed from V- and C1-type Ig folds,
cell-surface proteins such as the carcinoembryonic antigen
(CEA) are constructed from combinations of V-, C1-, C2-
and/or I-type Ig folds [2]. Structures by both crystallography
and constrained scattering modelling show that Ig folds are
arranged as extended single chains or form associations with
other chains via domain pairs [3^5]. This superfamily is fre-
quently involved in protein^protein interactions. The single
chain Fv antibody molecule MFE23 has a nanomolar a⁄nity
for CEA, an important tumour marker in colorectal cancer
[6,7]. We have determined the crystal structure of unliganded
MFE23 [8]. In this structure, there is a large region of contact
between the three antigen-binding loops H1, H2 and H3 of
MFE23 and the L-sheet of an adjacent MFE23 molecule.
These intermolecular contacts displayed remarkably high sur-
face and electrostatic complementarity. Several individual
MFE23 loop residues that participate in these contacts are
involved in CEA binding as supported by site-speci¢c muta-
genesis [8].
A structure for CEA is required for modelling the structure
of its complex with MFE23. As its 50% carbohydrate content
has precluded attempts to crystallise it, an alternative strategy
based on small-angle X-ray and neutron scattering data and
modelling based on V- and C2-type Ig folds showed that its
structure is well represented by an extended zig-zag domain
arrangement [4]. This curve modelling was based on a recently
developed automated strategy directly constrained using
known atomic structures [9], which is advantageous compared
to the recent use of spherical harmonics or genetic algorithms
for modelling proteins which do not make use of these known
structures in curve ¢ts. Since then, an I-type Ig domain was
shown to exist that is structurally distinct from the C2-type
domain, of which three copies occur in CEA [2,10]. I-type
crystal structures for two cell-surface proteins have been de-
termined [11^14]. These developments enable signi¢cantly im-
proved homology models for each of the seven glycosylated
domains of CEA to be constructed. Accordingly we present a
full model for CEA and validate it with small-angle X-ray and
neutron scattering data.
The combination of experimentally deduced structures for
MFE23 and CEA with the observed intermolecular lattice
contacts seen in the crystal structure of MFE23 enabled a
model for their complex to be constructed by superimposition
based on structural homology between the MFE23 and CEA
domains. The model was well-supported by good surface and
electrostatic complementarity and carbohydrate-unhindered
access. It is also supported by biochemical data and clari¢es
reasons for the high a⁄nity of the complex. Such a modelling
strategy may o¡er a new approach for structural predictions
of protein^protein complexes prior to crystal structure deter-
minations, which is otherwise computationally complex to
achieve [15].
2. Materials and methods
2.1. Seven homology models for the CEA domains
Homology models for the CEA-1 to CEA-7 domains (also known
as N, IA, IB, IIA, IIB, IIIA and IIIB in that order) were constructed
using INSIGHT II, BIOPOLYMER, HOMOLOGY and DISCOV-
ERY (MSI, San Diego, CA, USA) on Silicon Graphics INDY work-
stations. Loops were built using a database derived from 349 crystal
structures at 0.2 nm resolution or better [16]. Energy re¢nements
based on the consistent valence force ¢eld were performed at the
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loop splice junctions, then on the sidechain atoms of all residues in the
structurally conserved regions, and all the atoms of both types of loop
residues. Iterations were made using the steepest descent algorithm to
improve connectivities and minimise bad contacts or stereochemis-
tries. The secondary structure backbone was retained by ¢xing the
mainchain atoms in the conserved regions, and tethering these in
the loop regions. Models were veri¢ed using PROCHECK [17]. Sol-
vent accessibilities were calculated using a water molecule probe of
0.14 nm diameter in COMPARER [18,19]. Secondary structures were
identi¢ed using DSSP [20].
The CEA-1 domain (residues 1^108) was modelled using the
N-terminal V-type structures from the human cell surface proteins
CD2, CD4 and CD8 as templates in order to allow for insertions or
deletions in the loop regions (residues 4^104 in human CD2; residues
1^99 in human CD4; residues 2^114 in human CD8; protein data
bank (PDB) codes: 1hnf, 3cd4 and 1cd8 respectively) [21^23]. The
conserved L-strands (Fig. 1a) were superimposed using the conserved
Trp residue in L-strand C as a reference. Each of the 10 L-strands and
designated loops in the CEA-1 homology model was based on the
template with the highest sequence similarity to CEA-1 (underlined
in Fig. 1a). Eight structurally-conserved L-strands (37 residues) and
four designated conserved loops (39 residues) were identi¢ed, while
¢ve loops that displayed insertions and deletions were reconstructed
from database searches (32 residues: not underlined in Fig. 1a).
Homology models for the CEA-2 to CEA-7 domains were con-
structed as follows. Residues 3^94 of the CEA-2, CEA-4 and CEA-
6 domains were modelled using residues 1^90 in human vascular cell
adhesion molecule-1 (VCAM-1) which is an I-type domain (PDB
code: 1vca-A) [11]. This utilised seven structurally conserved L-strand
regions (38 residues), seven designated loops (50 residues) and one
searched loop (four residues) that corresponded to an insertion be-
tween L-strands F and G at residues 78^81 (Fig. 1b). Residues 2^84 of
the CEA-3, CEA-5 and CEA-7 domains were modelled using residues
104^181 of human CD2 (PDB code: 1cd8) [23]. This utilised seven
structurally conserved L-strand regions (29 residues), six designated
loops (38 residues) and two searched loops that corresponded to short
insertions or deletions (16 residues) between L-strands A and B and
L-strands F and G (Fig. 1c).
Two full models of CEA were created by superimposition of the
seven homology models onto each of the best-¢t and CD2-derived
CEA models determined by small-angle X-ray and neutron scattering
[4]. The inter-domain linker residues (nine residues) were represented
by searched loops. Triantennary carbohydrate structures Man3-
GlcNAc6Gal3Fuc3NeuNAc1 was added to each of the 28 putative
N-linked sites on each CEA model as before. Electrostatic surfaces
were calculated using DELPHI (MSI, San Diego, CA, USA). Red
represents a potential of less than 34 kT (acidic), blue a potential
of more than +4 kT (basic) and white as 0 kT (neutral).
2.2. Scattering curve ¢ts for CEA
Debye sphere models were created by placing the atomic coordi-
nates of the two CEA models in a three-dimensional grid of cubes of
side 0.571 nm. A sphere of volume equal to a single cube was placed
at the centre of each cube if a speci¢ed number of atoms was present
in the cube. The sphere cuto¡ was based on the requirement that the
total volume of spheres was that of the dry volume [24], and this
model contained 970 spheres. Hydration is not detectable by neutron
scattering and was not considered. The hydration shell is observed in
X-ray scattering experiments, so a hydrated sphere model was created
by uniformly expanding the dry model in order to include the addi-
tional volume of hydration of 0.3 g H20/g of glycoprotein, based on
an electrostricted volume of 0.0245 nm3 per bound water molecule
[24]. Scattering curves for comparison with the experiment were cal-
culated by the Debye equation assuming a uniform sphere scattering
density in the program SCT [25]. This procedure has been tested with
crystal structures in a molecular weight range of 23 000^127 000 [26^
28]. A full-width-half-height wavelength spread of 10% for V of 1.0
nm and a beam divergence of 0.024 radian were used to correct the
calculated curve [27]. The agreement between the modelled and ex-
perimental curves was determined using the RG value derived from
the calculated curve in the same Q range used for experimental Guin-
ier ¢ts and the R-factor for the Q range extending to 2 nm31 [27].
3. Results and discussion
3.1. Homology modelling of the CEA domains
The seven domains of CEA had been previously classi¢ed
and modelled on the basis of Ig folds in the order V-C2-C2-
C2-C2-C2-C2 [1,4,29]. Since then, the second and fourth CEA
domains (CEA-2 and CEA-4) had been reassigned as I-type
domains [10]. I-type structures are intermediate between
V-type and C1-type structures. Using the standard Ig nomen-
Fig. 1. Sequence alignment used for the modelling of CEA based on homologous crystal structures. The 28 oligosaccharide sites in CEA are
denoted by bold underlining. Sequences are labelled with their PDB code, and underlined regions indicate the structures used to construct the
CEA homology models. The L-strands (E) identi¢ed by the DSSP program are labelled A to G. a: The V-type domain of CEA is compared
with the ¢rst V-type domain in CD2, CD4 and CD8. b: The three I-type domains of CEA are compared with that found in the ¢rst domain
of VCAM-1. The V-frame pro¢le that resulted in the assignment to an I-type domain is shown asterisked above the alignment. c: The three
C2-type domains of CEA are compared with that found in the second domain of the cell-surface protein CD2.
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clature for the sequential lettering of L-strands from A to F,
the I-type structure contains DEBA and APGFCCP L-sheets,
in distinction to the V-type structure with DEBA and
APGFCCPCQ L-sheets, the C1-type fold with DEBA and
GFCCP L-sheets, and the C2-type fold with EBA and
GFCCP L-sheets [2,30]. The determination of I-type crystal
structures for VCAM-1 and intercellular cell adhesion mole-
cule-2 (ICAM-2) [11^14] veri¢ed the existence of this struc-
ture. The previous alignment of the CEA-2, CEA-4 and CEA-
6 sequences with those of C2-type domains had resulted in
large deletions and insertions [4,29]. Fig. 1b showed that the
CEA-2, CEA-4 and CEA-6 sequences are well aligned with
the V-frame pro¢le used to identify I-type domains [10]. The
V-frame matches encompasses residues from L-strands B to
G, but not from L-strand A which has a distinct structure in
di¡erent domains (see below) [10]. Only position 18 in the
CEA-2, CEA-4 and CEA-6 domains and position 69 in the
CEA-6 domain are minor exceptions to the 18 residues that
de¢ne this pro¢le.
Homology models were created for the seven domains of
CEA (CEA-1 to CEA-7). In general, as expected for Ig folds,
the sequence identities with the Ig crystal structures used for
modelling were low at 12^20%, and this is increased to 28^
37% if residue similarities were considered [4]. There is a high
conservation of buried hydrophobic residues within L-strands.
The CEA-1 model was constructed from the superimposition
of the V-type domains from human CD2, CD4 and CD8
(Section 2). The ¢ve loops that had to be rebuilt were located
either at the N-terminal tip of the CEA-1 domain (i.e. in the
same location as the antigen-binding site in antibody V-type
domains) or at the exposed edge CQ L-strand in the
APGFCCPCQ L-sheet (Fig. 1a). The CEA-2, CEA-4 and
CEA-6 models were constructed from the I-type domain of
VCAM-1, whose sequence is very similar in length. As the
alignment of Fig. 1b indicated that only one small insertion
in a loop was needed, this provided the most straightforward
modelling template. A proline sometimes occurs between the
A and AP L-strands of I-type folds in VCAM-1 and ICAM-2
and de¢nes the switch between these [11,14]. Prolines are con-
served in CEA-2, CEA-4 and CEA-6 in this region at posi-
tions 3, 5 and 14, together with a conserved putative carbo-
hydrate site at position 10. As a choice of structure here was
not possible, the modelling of this segment is approximate.
There is also a one-residue displacement of the V-frame hy-
drophobic residues in L-strands C and G of VCAM-1. In
summary, compared to the C2-type derived modelling, the
changeover to an I-type structure repositioned residues pres-
ently assigned to L-strands AP and CP from the opposite face
of the L-sheet sandwich. This has the e¡ect of topologically
relocating the carbohydrate chains at Asn-118, Asn-297 and
Asn-474. The CEA-3, CEA-5 and CEA-7 models were based
on the C2-type domain from human CD2 and required only
two small insertions in loop regions (Fig. 1c).
3.2. Determination of full structural models for CEA
In the structure determination of CEA by small-angle X-ray
and neutron scattering, an automated analysis of 4096 ar-
rangements of one V-type and six C2-type Ig domains taken
unmodi¢ed from the crystal structure of CD2 were rotated
relative to each other in 15‡ steps. This had shown that
only elongated zig-zag domain arrangements with 28 extended
oligosaccharide chains ¢tted the data [4]. The mean interdo-
main rotation between two domains in the best-¢t CEA model
was determined to be within error of that seen in the CD2
crystal structure [4,21,31]. Here, two full structures for CEA
were created by superimpositions of the new homology mod-
els for CEA-1 to CEA-7 onto the Ig folds of both these pre-
vious CD2-derived seven-domain models (Section 2). Both
models were assessed using small-angle neutron and X-ray
scattering ¢ts using the data of [4]. Previously, to achieve a
good ¢t, di¡erent scattering densities for each of the protein
and carbohydrate components had to be used in addition to
the inclusion of a hydration shell in the X-ray modelling.
Here, both CEA homology models resulted in improved
X-ray and neutron curve ¢ts to the extent that only a single
scattering density sphere model was needed to obtain a good
¢t. The best-¢t CEA model had a modelled X-ray RG value of
7.9 nm, in good agreement with the experimental X-ray RG
Fig. 2. Comparison of the calculated small-angle X-ray and neutron scattering curves for the homology model of CEA with experimental
small-angle X-ray and neutron data. The seven CEA domains in each model are shown as K-carbon traces, whereas the carbohydrate chains
are represented in full. The corresponding sphere model (sphere diameter, 0.571 nm) is also shown. The calculated neutron curve was corrected
for wavelength resolution and beam divergence. For the experimental X-ray curve (a), the RG value is 7.9 nm and the R2:0 value for the X-ray
data is 4.4%. For the experimental neutron curve (a), the R1:7 value is 8.1%.
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value of 8.0 nm. The modelled X-ray RXS value was 1.9 nm, in
good agreement with the experimental X-ray RXS value of 2.1
nm. The small-angle X-ray and neutron R-factors were im-
proved to 4.3 and 8.2% respectively in place of the previous
values of 4.7 and 8.7%. The CD2-derived CEA model (Fig. 2)
had modelled X-ray RG and RXS values of 7.9 and 2.0 nm
respectively, and the small-angle X-ray and neutron R-factors
were also improved at 4.4 and 8.1% respectively. These im-
provements justify the incorporation of the seven domain ho-
mology models with extended carbohydrate chains to repre-
sent the CEA structure in solution.
3.3. A model for the complex between MFE23 and CEA
The prediction of a structural model for the complex be-
tween MFE23 and CEA was based on the intermolecular
contacts seen in the MFE23 crystal structure [8]. There, the
antigen-binding loops H1, H2 and H3 in the variable heavy
chain domain (VH) formed extensive interactions with the side
of the variable light chain domain (VL) of a neighbouring
MFE23 molecule. When this neighbouring VL MFE23 do-
main was superimposed with the N-terminal domain in the
two-domain crystal structures of CD2, CD4, ICAM-2 and
VCAM-1 [11,14,21,22] based on residues within the invariant
L-strands B, C, E and F, the six antigen binding loops of
MFE23 were seen in all four cases to be positioned within
the angled surface formed between the N-terminal and C-ter-
minal domains. All four superimpositions showed that the six
loops were positioned between the lower part of the DEBA
face of the N-terminal domain and the upper part of the GFC
face of the C-terminal domain. This is a di¡erent topology
from that seen within the MFE23 crystal structure, where
only the H1, H2 and H3 loops form good contacts. This
di¡erence is explained by noting that the two independent
VL and VH domains in adjacent MFE23 molecules in the
lattice are orientated antiparallel to each other, so only half
the expected contacts would be expected to be formed, in
contrast to the parallel arrangement of the Ig fold domains
in CD2 that is enforced by their covalent connection and
which permits a full set of contacts with MFE23 to be formed.
The MFE23^CEA complex was modelled by superimposing
MFE23 onto the N-terminal domain of the CD2-derived CEA
model. The CD2-derived structure was used in preference to
CD4, ICAM-2 and VCAM-1 structures for three reasons:
(i) the two CD2 domains formed the most favourable contacts
with MFE23 in the superimpositions, followed by those of
CD4; (ii) the length of the linker peptide between the two
CD2 domains is similar to those in CEA, while that for
CD4 is four residues shorter ; (iii) the domain pair in
ICAM-2 and VCAM-1 corresponded to an I-C2 arrangement
instead of the V-C2 arrangement of CD2 and CD4. The mod-
el for the complex assumed that no conformational changes
occur in the CEA interdomain angles or the MFE23 antigen-
binding loops on complex formation, which is considered
likely in view of the nanomolar a⁄nity of the complex.
3.4. Assessment of the model for the complex between MFE23
and CEA
The formation of antibody^antigen complexes involves a
Fig. 3. The predicted model of the MFE23 complex with CEA-1 and CEA-2. a: An electrostatic view of the CEA-1 and CEA-2 domains is
shown, where a stripe of basic residues (Lys-15, Arg-64, Lys-112, Lys-180, Arg-190 and Arg-191) at the interface between the CEA-1 and
CEA-2 domains is arrowed. b: The K-carbons of these six basic residues are shown as blue spheres in the ribbon view of the CEA homology
model (V-type, yellow; I-type, green) which is rotated by 180‡ about the vertical axis relative to the electrostatic view of the CEA-1 and CEA-
2 domains. These basic residues are complementary to a stripe of acidic residues seen on the MFE23 electrostatic surface. These acidic residues
are located on the H1 and H2 loops of MFE23 and at the N-terminus of the VL domain, and involve Asp-H31, Asp-H52, Glu-H53, Asp-H56,
Glu-H58 and Glu-L1. c: Comparison of the oligosaccharide arrangement in CEA relative to the modelled MFE23 binding site on CEA. A rib-
bon diagram of MFE23 (white) is shown attached to the CEA-1 and CEA-2 domains (yellow and green respectively), in which the CEA-1 and
CEA-2 domains are shown in the same orientation as the two domains in a. Seven oligosaccharide chains at Asn-70 and Asn-81 in CEA-1 and
at Asn-118, Asn-148, Asn-163, Asn-170 and Asn-174 in CEA-2 are shown in blue solid representations. These do not prevent MFE23 binding
at the interface between the CEA-1 and CEA-2 domains.
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combination of electrostatic and hydrophobic interactions at
the interface between the two proteins as well as good surface
complementarity [15,32^35]. Accordingly the electrostatic in-
teraction between MFE23 and CEA in the model was exam-
ined. In its antigen-binding loops, MFE23 presents negatively
charged residues at Asp-H31 (H1), and at Asp-H52, Glu-H53,
Asp-H56 and Glu-H58 (H2) (Kabat numbering is used
throughout), four of which are highly exposed. Together
with Glu-L1 in the MFE23 framework, these form a stripe
of six acidic residues across the surface of MFE23 (Fig. 3b).
The CEA homology model demonstrates a complementary
stripe of six basic residues (arrowed in Fig. 3a) across the
CEA-1 and CEA-2 domains. These include Lys-15 and Arg-
64 on the DEBA face of CEA-1 and Lys-112, Lys-180, Arg-
190 and Arg-191 on the GFC face of CEA-2, the positions of
which were well-de¢ned in the CEA homology modelling de-
scribed above. The K-carbon distances between the two sur-
faces showed that eight pairs of MFE23 and CEA residues
(Asp-H31/Lys-15, Asp-H31/Arg-64, Asp-H52/Lys-15, Glu-
H53/Lys-15, Asp-H56/Lys-15, Glu-H58/Lys-112, Glu-H58/
Arg-190 and Glu-H58/Arg-191) had separations between 1.0
and 1.4 nm. These are similar to the K-carbon separations of
1.1^1.4 nm (16 values) in Glu^Arg salt bridges between the
VH residues Glu-H35 and Glu-H50 and the lysozyme residues
Arg-45 and Arg-68 seen in crystal structures of Fab^lysozyme
complexes (PDB codes: 3h£, 1mlc and 2i¡) [32,33]. Of partic-
ular interest is the proximity of Lys-15 and Arg-64 of CEA-1
to the H2 loop of MFE23 in the model of the complex. These
CEA residues are structurally homologous to Lys-L18 and
Arg-L77 in the neighbouring molecule of MFE23 that form
intermolecular contacts with the H2 residues Asp-H52 and
Glu-H53 of MFE23 [8]. This o¡ers an explanation of how
the MFE23 intermolecular contacts can be used to model
the MFE23^CEA complex.
The shape complementarity of the MFE23 and CEA surfa-
ces at their interface in the complex was examined using a set
of 3Aî -thick slices of the Connolly surfaces for MFE23 and
CEA. The surfaces were satisfactorily accommodated at the
antibody^antigen interface. No unusual contacts were found
using the bump check facility in the WHATIF program avail-
able from the Internet at EMBL Heidelberg, when two atoms
are said to ‘bump’ if they are closer than the sum of their van
der Waals radii minus 0.4 Aî . The total surface area lost in
complex formation is 738 Aî 2, which is within the range of the
corresponding values of 632^916 Aî 2 reported in six antibody^
antigen crystal structures [32]. In the MFE23^CEA complex,
the percentage surface areas lost for each of the six loops H1,
H2, H3, L1, L2 and L3 were 13, 5, 42, 25, 4 and 12% in that
order, and these values are as expected from known antibody^
antigen crystal structures [34,35]. The CEA sidechains of Lys-
15, Arg-64, Lys-180, Arg-190 and Arg-191 showed decreased
accessible surfaces of 11^38 Aî 2 in the complex, and likewise
the MFE23 sidechains of Asp-H31, Asp-H52 and Glu-H53
showed decreased accessible surfaces, as expected from their
K-carbon separations.
The 28 carbohydrate chains of CEA may obstruct the
MFE23 binding site. Scattering indicates that the carbohy-
drate is on average extended freely into solution [4]. Fig. 3c
showed that the glycosylation site at Asn-70 was located at
the top of the CEA-1 domain, while Asn-81 was located at the
GFC face on the opposite side of the CEA-1 domain to where
MFE23 is located. The ¢ve glycosylation sites on the CEA-2
domain at Asn-118, Asn-148, Asn-163, Asn-170 and Asn-174
were located around the base of the CEA-2 domain. All seven
Asn residues had unchanged solvent accessibilities in the mod-
el of the complex. Visual inspection with stereo glasses
showed no steric overlap of the seven carbohydrate chains
with MFE23 (Fig. 3c). This was con¢rmed using the bump
check facility in WHATIF. The inspection of the carbohy-
drate sites at the ¢ve remaining interdomain junctions in
CEA did not favour a MFE23 binding site at any of these
(Fig. 4a). Sixteen sites were located to the DEBA faces, and
10 to the GFC faces. MFE23 was successively superimposed
onto the N-terminal domain at each junction in the CD2-
derived full CEA model. At each position, the relationship
of MFE23 to nearby carbohydrate chains was checked using
stereo glasses. This showed that each of these ¢ve potential
sites would be blocked by each of Asn-275, Asn-222, Asn-446,
Asn-398, or Asn-631 in turn (Fig. 4a). It is possible that the
role of carbohydrate at these sites may maintain CEA as an
extended zig-zag structure that protrudes perpendicular from
the cell surface, and that Asn-578 and Asn-616 may perform a
similar function at the cell surface.
The interaction between MFE23 and CEA has been exam-
ined using four VH mutated forms of MFE23 [36]. A Tyr-
H100b to Pro mutation abolished MFE23 binding to CEA;
the sidechain surface accessibility of Tyr-H100b is 62% in
MFE23 and 0% in the model of the MFE23^CEA complex.
A Glu-H53 to Lys mutation decreased MFE23 binding to
CEA; the corresponding accessibility of Glu-H53 is 60% in
MFE23 and 31% in the MFE23^CEA complex. A Thr-H98 to
Ala mutation led to a minor improvement in MFE23 binding
to CEA; the accessibility of Thr-H98 was 99% in MFE23 and
3% in the MFE23^CEA complex. A Tyr-H100a to Ala muta-
tion had no e¡ect on MFE23 binding to CEA; the accessi-
Fig. 4. Predicted association of MFE23 with the domains of CEA.
a: The seven CEA domains are shown as ellipsoids with MFE
(circles) bound at all six possible interfaces between adjacent do-
main pairs. The MFE23 binding site between the CEA-1 and CEA-
2 domains is boldface. The DEBA face of each CEA domain is
shown hatched, and the GFC face is shown open. The 28 carbohy-
drate sites are represented by b, where each one is identi¢ed by its
Asn residue number. The number is positioned outside the MFE23
circle if the Asn residue o¡ers no steric hindrance to MFE23 bind-
ing, and inside if there is steric overlap. b: MFE23 is shown as a
black ribbon at its predicted binding site in a ribbon view of the
full CD2-derived model of CEA. The 28 oligosaccharide chains are
shown as black outlines.
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bility of Tyr-H100a is unchanged at 6% in both MFE23 and
the MFE23^CEA complex. The outcome of these experimen-
tal mutagenesis studies are fully consistent with the model of
the MFE23^CEA complex.
4. Conclusions
In this study, recent advances in structural analyses of the
Ig superfamily has resulted in an improved full homology
model for CEA that was validated by means of solution scat-
tering curve ¢ts (Fig. 2). This model has been deposited in the
PDB (code 1e07). MFE23 was developed by phage technology
as an antibody molecule with a high nanomolar a⁄nity for its
target molecule CEA [6]. By combining the CEA model with
the observed intermolecular contacts in our crystal structure
of MFE23 [8], a plausible molecular model for the complex
between MFE23 and CEA could be constructed (Fig. 4b). The
model for the complex between MFE23 and CEA is sup-
ported by mutagenesis using MFE23 [36] and by experimental
evidence that showed that MFE23 binds to a double-domain
CEA-1 and CEA-2 fragment expressed in E. coli (Thornton,
J.D., Keep, P.A., Chester, K.A. and Begent, R.H.J., unpub-
lished results). In particular, the model showed that all six
antigen-binding loops interacted with CEA, thus o¡ering an
explanation of the high a⁄nity of MFE23 for CEA. It also
indicated six potential electrostatic ion-pairs that may stabilise
the a⁄nity of MFE23 for CEA, two of which were homolo-
gous to those seen in the intermolecular contacts in the
MFE23 crystal structure. Furthermore, the extensive buried
surface area of this model is consistent with what is seen in
antigen^antibody crystal structures; and no steric con£ict was
observed with any of the 28 carbohydrate chains in CEA. As
far as is known, a docking procedure for the modelling of an
antibody^antigen complex based on antibody crystallographic
intermolecular contacts has not been previously described
[15]. A related approach was largely successful in predicting
the structure of the cell-surface complex formed between CD2
and CD58, which is stabilised by ¢ve salt bridges [37,38]. In
an independent approach using mutagenesis, electrostatic
forces have been shown to be important for stabilising the
complex between the monoclonal antibody 2E8 and apolipo-
protein E [39]. It is not possible to verify the model for the
MFE23^CEA complex by scattering, as MFE23 is too small
compared to CEA to permit its localisation relative to CEA
(Fig. 4). We are presently attempting crystal structure strat-
egies for this complex, which if successful will make possible
the critical evaluation of the success of this modelling proce-
dure in prediction work. At the present time, the model makes
possible the rational interpretation of current biochemical and
molecular biology experiments designed to improve the under-
standing of the binding a⁄nity of MFE23 to CEA and the
tumour targeting properties of MFE23.
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